Le Lézard
Classified in: Health
Subjects: SVY, MAT

Medical Marijuana Cards Often Sought by Existing Heavy Users: Journal of Studies on Alcohol and Drugs


PISCATAWAY, N.J., Dec. 4, 2019 /PRNewswire/ -- Young adults who seek enrollment in state medical marijuana programs are often those who already use heavily rather than those with health issues that could be addressed by the drug. That's according to new results published in the Journal of Studies on Alcohol and Drugs.

"Making medical marijuana cards easy to obtain for vaguely defined mental or physical health conditions that are not supported by any research evidence has potential for those who use more heavily to claim need for a medical marijuana card solely to have easier access," says lead author Eric R. Pedersen, Ph.D., of the RAND Corporation in Santa Monica, California.

The researchers analyzed data from a long-term study of substance use prevention in California. Participants were followed from middle school through young adulthood. The current analysis contained data from 264 participants who were 18 to 20 years old in 2015 to 2017, when medical marijuana was legal in California but before outlets in that state were allowed to sell legal recreational marijuana in 2018.

At the start, participants had to have used marijuana at least once in the past month, but none had obtained a "medical marijuana card," which would allow them to buy and use the drug. Both initially and one year later, they were asked about their marijuana use, symptoms of depression and anxiety and physical health problems.

After one year, 19 percent of participants had sought out and received a medical marijuana card. Overall, men were 2.91 times as likely as women to have received a card at follow-up.

In addition, for every additional day of marijuana use at the beginning of the study, the odds of receiving a medical marijuana card increased seven percent one year later. After statistically controlling for confounding variables, the authors found that physical and mental health problems at baseline (i.e., the problems ostensibly one would seek a medical marijuana card for) were not significant predictors of receiving a card in that follow-up period.

"Many individuals ... struggle with legitimate medical and psychological concerns that can benefit from medical marijuana," according to the authors. In California, the qualifying conditions include chronic pain, glaucoma and seizures, among others. However, the law is also general enough that providers can recommend the drug to patients with "any other chronic or persistent medical symptom" that may limit "major life activities."

Pedersen adds that providers should consider reviewing types of symptom management other than, or in addition to, medical marijuana and look for signs that the drug has impacted patients in a negative way.

To arrange an interview with Eric R. Pedersen, please contact Warren Robak at RAND Media Relations: (310) 451-6913 or robak@rand.org.

https://www.jsad.com/doi/abs/10/15288/jsad.2019.80.687

Related Images
image1.jpg

Related Links
Journal of Studies on Alcohol and Drugs
Study full text

SOURCE Journal of Studies on Alcohol and Drugs


These press releases may also interest you

at 02:05
Today, Excelya, a leading contract research organization (CRO) specializing in clinical research, announced that three European CROs joined Excelya Group: Zeincro based in Central-Eastern & Southern Europe, The Clinical Company based in the...

at 02:05
Masimo today announced the results of a study published in Pneumonia in which independent researchers in New Delhi, India, investigated the accuracy of Masimo RRp® on pediatric patients with the Rad-Gtm Pulse Oximeter by comparing it to...

at 02:00
With one in five people suffering from the annual attack of itchy red eyes and constant sneezing, and with the pollen count set for HIGH, on-demand laundry app, Laundrapp, shares its top five tips ? from bedding to intimacy ? for protecting against...

at 01:35
Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 ? ALSEN) a pioneering, clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders,...

at 01:35
Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central...

at 01:00
Ascentage Pharma (6855.HK), a global, clinical-stage biotechnology company developing novel therapies for cancers, chronic hepatitis B (CHB), and senesce diseases, today announced a clinical collaboration with MSD to evaluate the combination of...



News published on 4 december 2019 at 01:00 and distributed by: